Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -189.22% is 93% below its 5-year average of -98.28%, around the middle of its 5-year range (-280.94%–-16.56%).
85.10% below its 12-month average of -102.23%.
Reported quarterly return on assets; no daily interpolation. Q1 FY2027 (2026-06-30): -36.46%.
RETURN ON ASSETS (ROA)
-189.22%
RETURN ON ASSETS (ROA) AVG TTM
-102.23%
RETURN ON ASSETS (ROA) AVG 3Y
-127.28%
RETURN ON ASSETS (ROA) AVG 5Y
-98.28%
RETURN ON ASSETS (ROA) AVG 10Y
-572.66%
RETURN ON ASSETS (ROA) AVG 15Y
-342.99%
RETURN ON ASSETS (ROA) AVG 20Y
-387.11%
CURRENT VS TTM AVG
-85.10%
CURRENT VS 3Y AVG
-48.66%
CURRENT VS 5Y AVG
-92.53%
CURRENT VS 10Y AVG
+66.96%
CURRENT VS 15Y AVG
+44.83%
CURRENT VS 20Y AVG
+51.12%
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-486.91%
vs the sector median at left
VistaGen Therapeutics, Inc.
Market Cap
$11.12M
Return on Assets (ROA)
-189.22%
TTM Avg
-102.23%
3Y Avg
-127.28%
5Y Avg
-98.28%
Market Cap
$11.08M
Return on Assets (ROA)
-46.21%
TTM Avg
-17.41%
3Y Avg
-49.70%
5Y Avg
-52.01%
Market Cap
$11.02M
Return on Assets (ROA)
-132.59%
TTM Avg
-75.28%
3Y Avg
-65.73%
5Y Avg
-52.31%
Market Cap
$11.00M
Return on Assets (ROA)
N/A
TTM Avg
-37.02%
3Y Avg
-41.41%
5Y Avg
-41.74%
Market Cap
$10.94M
Return on Assets (ROA)
-185.94%
TTM Avg
-166.39%
3Y Avg
-133.67%
5Y Avg
-110.62%
Market Cap
$11.36M
Return on Assets (ROA)
-404.58%
TTM Avg
-269.82%
3Y Avg
-269.82%
5Y Avg
-269.82%
Market Cap
$10.86M
Return on Assets (ROA)
-154.89%
TTM Avg
-40.68%
3Y Avg
-87.98%
5Y Avg
-439.28%
Market Cap
$10.83M
Return on Assets (ROA)
N/A
TTM Avg
-21.71%
3Y Avg
-73.35%
5Y Avg
-116.85%
Market Cap
$11.55M
Return on Assets (ROA)
-90.19%
TTM Avg
-82.55%
3Y Avg
-92.57%
5Y Avg
-79.83%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| VistaGen Therapeutics, Inc. (VTGN) | $11.12M | -189.22% | -102.23% | -127.28% | -98.28% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | -46.21% | -17.41% | -49.70% | -52.01% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | -132.59% | -75.28% | -65.73% | -52.31% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | -37.02% | -41.41% | -41.74% |
| Cerenome, Inc. (CNSY)vs › | $10.94M | -185.94% | -166.39% | -133.67% | -110.62% |
| Caring Brands, Inc. (CABR)vs › | $11.36M | -404.58% | -269.82% | -269.82% | -269.82% |
| BioVie Inc. (BIVI)vs › | $10.86M | -154.89% | -40.68% | -87.98% | -439.28% |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | -21.71% | -73.35% | -116.85% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.55M | -90.19% | -82.55% | -92.57% | -79.83% |
| Pluri Inc. (PLUR)vs › | $10.68M | -98.26% | -77.06% | -65.68% | -62.77% |
ROA
-189.2%
ROE
-276.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -143.49% |
| 2025-03-31 | -60.96% |
| 2024-03-31 | -23.75% |
| 2023-03-31 | -280.94% |
| 2022-03-31 | -63.99% |
| 2021-03-31 | -16.56% |
| 2020-03-31 | -359.89% |
| 2019-03-31 | -175.49% |
| 2018-03-31 | -127.20% |
| 2017-03-31 | -276.26% |
| 2016-03-31 | -4770.71% |
| 2015-03-31 | -5148.61% |
| 2014-03-31 | -1125.41% |
| 2013-03-31 | -1461.91% |
| 2012-03-31 | -3574.21% |
| 2010-12-31 | -408.00% |
| 2009-12-31 | -1598.69% |
| 2008-12-31 | -71.19% |
| 2007-12-31 | 0.00% |
